Advertisement
0006| Volume 128, SUPPLEMENT , 154969, March 2022

Blood based biomarkers as non-invasive screening tools for hepatic fibrosis in subjects with Type 2 Diabetes Mellitus

DOI:https://doi.org/10.1016/j.metabol.2021.154969
Blood based biomarkers as non-invasive screening tools for hepatic fibrosis in subjects with Type 2 Diabetes Mellitus
Previous ArticleFactors associated with hepatic steatosis in adult Greek subjects with type 2 diabetes mellitus
Next ArticleDevelopment of Cardiac specific Neurohormonal based diagnostic marker for Diabetes linked cardiac failure
      Background: NAFLD is dramatically increasing in parallel with the pandemic of Type 2 Diabetes Mellitus (T2DM). Objectives: We aimed to assess the performance of the most commonly used non-invasive blood biomarkers for liver fibrosis in subjects with T2DM.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Identification

      DOI: https://doi.org/10.1016/j.metabol.2021.154969

      Copyright

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX